Provention Bio, Inc.
(NASDAQ : PRVB)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
ABBVAbbVie, Inc. -1.71%89.161.9%$1148.20m
JNJJohnson & Johnson -0.51%143.820.7%$1050.16m
BMYBristol-Myers Squibb Co. -0.53%60.001.0%$962.01m
MRKMerck & Co., Inc. -0.28%77.050.7%$832.10m
PFEPfizer Inc. -0.72%37.220.9%$825.45m
LLYEli Lilly & Co. -2.51%144.251.1%$413.20m
AZNAstraZeneca Plc -2.41%51.831.2%$248.03m
NVSNovartis AG -1.12%84.100.2%$155.03m
GSKGlaxoSmithKline Plc -0.09%40.720.2%$137.24m
NVONovo Nordisk A/S -1.61%62.380.1%$84.26m
SNYSanofi -0.05%47.250.2%$79.52m
RGENRepligen Corp. -5.56%125.937.1%$65.99m
BHVNBiohaven Pharmaceutical Holding Co. Ltd. -2.44%58.550.0%$44.66m
ARCTArcturus Therapeutics Holdings, Inc. -27.19%39.540.0%$40.07m
RETAReata Pharmaceuticals, Inc. -4.59%150.523.4%$36.05m

Company Profile

Provention Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics and solutions. Its products include PRV-031 for the interception of type 1 diabetes (T1D); PRV-015 for the treatment of gluten-free diet non-responding celiac disease; PRV-6527 for Crohn's disease; PRV-3279 for the treatment of lupus; and PRV-101 for the prevention of acute coxsackie virus B (CVB), and the prevention of type 1 diabetes (T1D) onset. The company was founded by Francisco Leon and Ashleigh Palmer on October 4, 2016 and is headquartered in Lebanon, NJ.